Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/YZacks Investment Research • 02/22/24
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/31/24
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?Zacks Investment Research • 01/29/24
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/19/23
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription AgreementsGlobeNewsWire • 12/07/23
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/30/23
UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability ReportGlobeNewsWire • 11/14/23
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF DeviceGlobeNewsWire • 11/02/23
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial GuidanceGlobeNewsWire • 10/31/23
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/24/23
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorganMarket Watch • 10/24/23